Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
Disease control
Recruiting now
This phase 3 trial is testing whether an investigational drug called INT230-6, which combines three anti-cancer agents and is injected directly into tumors, can help people with advanced soft tissue sarcoma live longer than those receiving standard care. The study enrolls adults …
Phase: PHASE3 • Sponsor: Intensity Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC